These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7906050)

  • 1. Markov models. MAP Workshop (Multi-cohort Analysis Project).
    Stat Med; 1993 Nov; 12(22):2127-30. PubMed ID: 7906050
    [No Abstract]   [Full Text] [Related]  

  • 2. Marker paths. MAP Workshop (Multi-cohort Analysis Project).
    Stat Med; 1993 Nov; 12(22):2099-126. PubMed ID: 7906049
    [No Abstract]   [Full Text] [Related]  

  • 3. Markers as time-dependent covariates in relative risk regression. MAP Workshop (Multi-cohort Analysis Project).
    Stat Med; 1993 Nov; 12(22):2087-98. PubMed ID: 7906048
    [No Abstract]   [Full Text] [Related]  

  • 4. Extending public health surveillance of HIV infection: information from a five cohort workshop. MAP Workshop (Multi-cohort Analysis Project).
    Stat Med; 1993 Nov; 12(22):2065-85. PubMed ID: 7906047
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune serum markers and CD4 cell counts in HIV-infected intravenous drug users.
    Chaisson RE; Taylor E; Margolick JB; Muñoz A; Solomon L; Cohn S; Nelson KE; Vlahov D
    J Acquir Immune Defic Syndr (1988); 1992; 5(5):456-60. PubMed ID: 1348535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of the predictive value of CD4+ lymphocyte count by beta 2-microglobulin, immunoglobulin A and erythrocyte sedimentation rate. The Multicentre Cohort Study Group.
    Schwartländer B; Bek B; Skarabis H; Koch J; Burkowitz J; Koch MA
    AIDS; 1993 Jun; 7(6):813-21. PubMed ID: 8103341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-state Markov models for analysing incomplete disease history data with illustrations for HIV disease.
    Gentleman RC; Lawless JF; Lindsey JC; Yan P
    Stat Med; 1994 Apr; 13(8):805-21. PubMed ID: 7914028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and beta 2-microglobulin are not adequate to estimate time of HIV infection. Multicohort Analysis Project Workshop. Part II.
    AIDS; 1994 Jul; 8(7):923-33. PubMed ID: 7946101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
    Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
    Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and laboratory correlates of human immunodeficiency virus infection in a cohort of intravenous drug users from New York, NY.
    el-Sadr W; Goetz RR; Sorrell S; Joseph M; Ehrhardt A; Gorman JM
    Arch Intern Med; 1992 Aug; 152(8):1653-9. PubMed ID: 1353953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV and AIDS in the European Union, 2009.
    Likatavicius G; Van de Laar MJ
    Euro Surveill; 2010 Dec; 15(48):. PubMed ID: 21144450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tracking of markers and onset of disease among HIV-1 seroconverters.
    Galai N; Muñoz A; Chen K; Carey VJ; Chmiel J; Zhou SY
    Stat Med; 1993 Nov; 12(22):2133-45. PubMed ID: 7906051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users.
    Alcabes P; Muñoz A; Vlahov D; Friedland G
    Ann Epidemiol; 1994 Jan; 4(1):17-26. PubMed ID: 7911376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune activation markers and CD4+ T-cell counts in HIV-infected intravenous drug users.
    Zangerle R; Wachter H; Fuchs D
    J Acquir Immune Defic Syndr (1988); 1992 Dec; 5(12):1273-4. PubMed ID: 1360538
    [No Abstract]   [Full Text] [Related]  

  • 16. Markers of risk in HIV-1.
    Krämer A; Biggar RJ; Goedert JJ
    N Engl J Med; 1990 Jun; 322(26):1886. PubMed ID: 1971915
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term zidovudine therapy in patients with AIDS and symptomatic and asymptomatic HIV infection.
    Ebert S; Gockel K; Horowitz S; Weber P; Vogelman B; Graziano F
    Wis Med J; 1991 Apr; 90(4):161-5. PubMed ID: 1675028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum B2-microglobulin and human immunodeficiency virus infection in intravenous drug users: a cross-sectional study.
    De Mercato R; Rezza G; Giuliani M; Perna E; Iovinella V; Bassi A; Tagliaferro R
    Boll Ist Sieroter Milan; 1990 Jun; 69(2):447-8. PubMed ID: 2152304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Children born to women with HIV-1 infection: natural history and risk of transmission. European Collaborative Study.
    Lancet; 1991 Feb; 337(8736):253-60. PubMed ID: 1671109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV/AIDS surveillance in Indiana.
    Fleissner ML
    Indiana Med; 1992; 85(6):486-9. PubMed ID: 1431033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.